Edesa Biotech (EDSA) Competitors

Edesa Biotech logo
$2.06 +0.10 (+5.10%)
Closing price 04:00 PM Eastern
Extended Trading
$2.05 -0.01 (-0.49%)
As of 06:47 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

EDSA vs. KZIA, COYA, CRBP, GOSS, and CRDF

Should you buy Edesa Biotech stock or one of its competitors? Edesa Biotech's main competitors and comparable companies include Novogen (KZIA), Coya Therapeutics (COYA), Corbus Pharmaceuticals (CRBP), Gossamer Bio (GOSS), and Cardiff Oncology (CRDF). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Edesa Biotech compare to Novogen?

Edesa Biotech (NASDAQ:EDSA) and Novogen (NASDAQ:KZIA) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, analyst recommendations, media sentiment, profitability, dividends, earnings, risk and institutional ownership.

Novogen's return on equity of 0.00% beat Edesa Biotech's return on equity.

Company Net Margins Return on Equity Return on Assets
Edesa BiotechN/A -560.22% -105.74%
Novogen N/A N/A N/A

Edesa Biotech has higher earnings, but lower revenue than Novogen.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Edesa BiotechN/AN/A-$7.19M-$1.69N/A
Novogen$1.23M55.99-$13.41MN/AN/A

In the previous week, Edesa Biotech had 1 more articles in the media than Novogen. MarketBeat recorded 3 mentions for Edesa Biotech and 2 mentions for Novogen. Edesa Biotech's average media sentiment score of 0.95 beat Novogen's score of 0.42 indicating that Edesa Biotech is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Edesa Biotech
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Novogen
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

5.5% of Edesa Biotech shares are held by institutional investors. Comparatively, 30.9% of Novogen shares are held by institutional investors. 24.4% of Edesa Biotech shares are held by company insiders. Comparatively, 1.0% of Novogen shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Edesa Biotech has a beta of 1.26, indicating that its share price is 26% more volatile than the broader market. Comparatively, Novogen has a beta of 2.34, indicating that its share price is 134% more volatile than the broader market.

Novogen has a consensus price target of $29.50, suggesting a potential upside of 455.56%. Given Novogen's stronger consensus rating and higher probable upside, analysts plainly believe Novogen is more favorable than Edesa Biotech.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Edesa Biotech
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
1 Strong Buy rating(s)
2.50
Novogen
1 Sell rating(s)
0 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
2.78

Summary

Novogen beats Edesa Biotech on 8 of the 13 factors compared between the two stocks.

How does Edesa Biotech compare to Coya Therapeutics?

Coya Therapeutics (NASDAQ:COYA) and Edesa Biotech (NASDAQ:EDSA) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, media sentiment, profitability, institutional ownership, earnings, valuation and dividends.

39.8% of Coya Therapeutics shares are owned by institutional investors. Comparatively, 5.5% of Edesa Biotech shares are owned by institutional investors. 6.1% of Coya Therapeutics shares are owned by company insiders. Comparatively, 24.4% of Edesa Biotech shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Edesa Biotech has lower revenue, but higher earnings than Coya Therapeutics. Coya Therapeutics is trading at a lower price-to-earnings ratio than Edesa Biotech, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Coya Therapeutics$7.95M8.91-$21.23M-$1.39N/A
Edesa BiotechN/AN/A-$7.19M-$1.69N/A

Coya Therapeutics presently has a consensus target price of $15.00, indicating a potential upside of 396.69%. Given Coya Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Coya Therapeutics is more favorable than Edesa Biotech.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Coya Therapeutics
1 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.67
Edesa Biotech
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
1 Strong Buy rating(s)
2.50

Edesa Biotech has a net margin of 0.00% compared to Coya Therapeutics' net margin of -643.44%. Coya Therapeutics' return on equity of -71.48% beat Edesa Biotech's return on equity.

Company Net Margins Return on Equity Return on Assets
Coya Therapeutics-643.44% -71.48% -63.57%
Edesa Biotech N/A -560.22%-105.74%

In the previous week, Coya Therapeutics had 9 more articles in the media than Edesa Biotech. MarketBeat recorded 12 mentions for Coya Therapeutics and 3 mentions for Edesa Biotech. Edesa Biotech's average media sentiment score of 0.95 beat Coya Therapeutics' score of -0.05 indicating that Edesa Biotech is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Coya Therapeutics
2 Very Positive mention(s)
2 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Edesa Biotech
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Coya Therapeutics has a beta of 0.7, suggesting that its stock price is 30% less volatile than the broader market. Comparatively, Edesa Biotech has a beta of 1.26, suggesting that its stock price is 26% more volatile than the broader market.

Summary

Coya Therapeutics beats Edesa Biotech on 9 of the 15 factors compared between the two stocks.

How does Edesa Biotech compare to Corbus Pharmaceuticals?

Edesa Biotech (NASDAQ:EDSA) and Corbus Pharmaceuticals (NASDAQ:CRBP) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, media sentiment, risk, analyst recommendations, earnings, dividends and profitability.

Edesa Biotech has a beta of 1.26, indicating that its stock price is 26% more volatile than the broader market. Comparatively, Corbus Pharmaceuticals has a beta of 2.8, indicating that its stock price is 180% more volatile than the broader market.

Corbus Pharmaceuticals' return on equity of -100.96% beat Edesa Biotech's return on equity.

Company Net Margins Return on Equity Return on Assets
Edesa BiotechN/A -560.22% -105.74%
Corbus Pharmaceuticals N/A -100.96%-82.70%

5.5% of Edesa Biotech shares are owned by institutional investors. Comparatively, 64.6% of Corbus Pharmaceuticals shares are owned by institutional investors. 24.4% of Edesa Biotech shares are owned by company insiders. Comparatively, 3.5% of Corbus Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Corbus Pharmaceuticals had 15 more articles in the media than Edesa Biotech. MarketBeat recorded 18 mentions for Corbus Pharmaceuticals and 3 mentions for Edesa Biotech. Edesa Biotech's average media sentiment score of 0.95 beat Corbus Pharmaceuticals' score of 0.10 indicating that Edesa Biotech is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Edesa Biotech
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Corbus Pharmaceuticals
2 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Edesa Biotech is trading at a lower price-to-earnings ratio than Corbus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Edesa BiotechN/AN/A-$7.19M-$1.69N/A
Corbus PharmaceuticalsN/AN/A-$78.54M-$6.10N/A

Corbus Pharmaceuticals has a consensus price target of $35.67, indicating a potential upside of 1,084.94%. Given Corbus Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Corbus Pharmaceuticals is more favorable than Edesa Biotech.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Edesa Biotech
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
1 Strong Buy rating(s)
2.50
Corbus Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.71

Summary

Corbus Pharmaceuticals beats Edesa Biotech on 8 of the 13 factors compared between the two stocks.

How does Edesa Biotech compare to Gossamer Bio?

Edesa Biotech (NASDAQ:EDSA) and Gossamer Bio (NASDAQ:GOSS) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, institutional ownership, risk, analyst recommendations, profitability, earnings, valuation and media sentiment.

In the previous week, Gossamer Bio had 17 more articles in the media than Edesa Biotech. MarketBeat recorded 20 mentions for Gossamer Bio and 3 mentions for Edesa Biotech. Edesa Biotech's average media sentiment score of 0.95 beat Gossamer Bio's score of 0.16 indicating that Edesa Biotech is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Edesa Biotech
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Gossamer Bio
2 Very Positive mention(s)
0 Positive mention(s)
5 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Neutral

Edesa Biotech has a beta of 1.26, indicating that its stock price is 26% more volatile than the broader market. Comparatively, Gossamer Bio has a beta of 2.28, indicating that its stock price is 128% more volatile than the broader market.

Edesa Biotech has higher earnings, but lower revenue than Gossamer Bio. Edesa Biotech is trading at a lower price-to-earnings ratio than Gossamer Bio, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Edesa BiotechN/AN/A-$7.19M-$1.69N/A
Gossamer Bio$48.47M1.39-$170.37M-$46.56N/A

5.5% of Edesa Biotech shares are owned by institutional investors. Comparatively, 81.2% of Gossamer Bio shares are owned by institutional investors. 24.4% of Edesa Biotech shares are owned by insiders. Comparatively, 4.2% of Gossamer Bio shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Gossamer Bio has a consensus target price of $246.40, indicating a potential upside of 2,131.88%. Given Gossamer Bio's higher probable upside, analysts clearly believe Gossamer Bio is more favorable than Edesa Biotech.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Edesa Biotech
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
1 Strong Buy rating(s)
2.50
Gossamer Bio
2 Sell rating(s)
3 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.30

Edesa Biotech has a net margin of 0.00% compared to Gossamer Bio's net margin of -159.49%. Gossamer Bio's return on equity of 0.00% beat Edesa Biotech's return on equity.

Company Net Margins Return on Equity Return on Assets
Edesa BiotechN/A -560.22% -105.74%
Gossamer Bio -159.49%N/A -112.10%

Summary

Edesa Biotech beats Gossamer Bio on 8 of the 15 factors compared between the two stocks.

How does Edesa Biotech compare to Cardiff Oncology?

Edesa Biotech (NASDAQ:EDSA) and Cardiff Oncology (NASDAQ:CRDF) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, earnings, profitability, media sentiment, dividends, analyst recommendations, risk and institutional ownership.

In the previous week, Cardiff Oncology had 4 more articles in the media than Edesa Biotech. MarketBeat recorded 7 mentions for Cardiff Oncology and 3 mentions for Edesa Biotech. Edesa Biotech's average media sentiment score of 0.95 beat Cardiff Oncology's score of 0.71 indicating that Edesa Biotech is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Edesa Biotech
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Cardiff Oncology
0 Very Positive mention(s)
2 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Edesa Biotech has a beta of 1.26, suggesting that its stock price is 26% more volatile than the broader market. Comparatively, Cardiff Oncology has a beta of 1.57, suggesting that its stock price is 57% more volatile than the broader market.

Cardiff Oncology has a consensus price target of $7.50, suggesting a potential upside of 786.11%. Given Cardiff Oncology's higher possible upside, analysts plainly believe Cardiff Oncology is more favorable than Edesa Biotech.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Edesa Biotech
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
1 Strong Buy rating(s)
2.50
Cardiff Oncology
1 Sell rating(s)
3 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.29

5.5% of Edesa Biotech shares are owned by institutional investors. Comparatively, 16.3% of Cardiff Oncology shares are owned by institutional investors. 24.4% of Edesa Biotech shares are owned by company insiders. Comparatively, 8.8% of Cardiff Oncology shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Edesa Biotech has higher earnings, but lower revenue than Cardiff Oncology. Cardiff Oncology is trading at a lower price-to-earnings ratio than Edesa Biotech, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Edesa BiotechN/AN/A-$7.19M-$1.69N/A
Cardiff Oncology$590K111.60-$45.85M-$0.55N/A

Edesa Biotech has a net margin of 0.00% compared to Cardiff Oncology's net margin of -6,736.49%. Cardiff Oncology's return on equity of -111.80% beat Edesa Biotech's return on equity.

Company Net Margins Return on Equity Return on Assets
Edesa BiotechN/A -560.22% -105.74%
Cardiff Oncology -6,736.49%-111.80%-81.51%

Summary

Cardiff Oncology beats Edesa Biotech on 9 of the 15 factors compared between the two stocks.

Get Edesa Biotech News Delivered to You Automatically

Sign up to receive the latest news and ratings for EDSA and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EDSA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

EDSA vs. The Competition

MetricEdesa BiotechBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$19.86M$3.97B$7.59B$11.72B
Dividend YieldN/A3.63%2.47%4.48%
P/E Ratio-1.2224.6233.5830.13
Price / SalesN/A15.448.255.59
Price / CashN/A22.9521.0121.90
Price / Book4.584.164.443.72
Net Income-$7.19M-$24.10M$3.50B$393.88M
7 Day Performance-7.21%-8.44%-6.53%-6.07%
1 Month Performance-19.84%-6.54%-4.93%-7.38%
1 Year Performance18.39%-6.71%-1.73%-7.48%

Edesa Biotech Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
EDSA
Edesa Biotech
1.378 of 5 stars
$2.06
+5.1%
N/A+13.0%$19.86MN/AN/A17
KZIA
Novogen
3.4676 of 5 stars
$5.31
-5.2%
$29.50
+455.6%
-12.7%$72.63M$1.23MN/A6
COYA
Coya Therapeutics
1.749 of 5 stars
$3.02
+0.7%
$15.00
+396.7%
-48.4%$70.37M$7.95MN/A8
CRBP
Corbus Pharmaceuticals
3.6313 of 5 stars
$3.01
-10.9%
$35.67
+1,084.9%
-73.2%$69.55MN/AN/A36
GOSS
Gossamer Bio
3.0292 of 5 stars
$11.04
+0.5%
$246.40
+2,131.9%
-95.4%$67.16M$48.47MN/A162

Related Companies and Tools


This page (NASDAQ:EDSA) was last updated on 11/18/2026 by MarketBeat.com Staff.
From Our Partners